Our understanding of the hepatic consequences of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection and its resultant coronavirus disease 2019 (COVID …

This study aimed to systematically assess COVID‐19 patient background characteristics and
pre‐existing comorbidities associated with hospitalisation status. The meta‐analysis …

Background: Little is known about real-world COVID-19 vaccine effectiveness (VE) in
racially and ethnically diverse, elderly populations with high comorbidity burden. Objective …

Importance Some persons infected with SARS-CoV-2 experience symptoms or impairments
many months after acute infection. Objectives To determine the rates, clinical setting, and …

Background Prospective population-based studies investigating multiple determinants of pre-
vaccination antibody responses to SARS-CoV-2 are lacking. Methods We did a prospective …

Background Persistent symptoms of SARS‐CoV‐2 are prevalent weeks to months following
the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS …

Post-COVID condition is prevalent in 10–35% of cases in outpatient settings, however a
stratification of the duration and severity of symptoms is still lacking, adding to the complexity …

Background and Aims Whether patients with cirrhosis have increased risk of severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and the extent to which …

Background mRNA COVID-19 vaccines manufactured by Pfizer-BioNTech (BNT162b2) and
Moderna (mRNA-1273) have been shown to be efficacious but have not been compared in …

The trajectories of acquired immunity to severe acute respiratory syndrome coronavirus 2
infection are not fully understood. We present a detailed longitudinal cohort study of UK …